Malin, the drug and biotech company, has said it will have sufficient cash to follow its money on key investments.
The company is slimming down its portfolio of 18 investments to focus on four potentially valuable companies.
Malin’s chief financial officer Darragh Lyons told The Sunday Business Post that while there might be requirements for these companies to raise more money, Malin would be able to meet its commitments through its existing cash, an undrawn European...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team